RxDoctor Payments Data

Natasha Khokhar

Family Practice · French Camp, CANPI 1871168286

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $684 of the $779 with a category attached, or 87.8%. 11 manufacturers reported payments, led by Astellas Pharma US Inc at 25.0% of the total. 2025 is the largest year on record at $583, more than ten times the $22 reported in 2022. Among family practice clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$779in general payments, 2019–2025

Across 29 payments — averaging $26.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$195
  • Pfizer$129
  • Amgen$106
  • Novo Nordisk$94
  • GSK$88
  • Otsuka America Pharmaceutical, Inc.$55
  • plus $112 from 5 others

What the payments were for

  • Food & beverage$68488%
  • Education$9512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc6$195
Pfizer4$129
Amgen4$106
Novo Nordisk4$94
GSK4$88
Otsuka America Pharmaceutical, Inc.2$55
AbbVie1$32
Gilead1$22
Merck1$22
Lilly USA, LLC1$19
RGH Enterprises LLC1$16

How this compares

$779 in reported general payments places this provider in the 95th percentile of 2,195 family practice providers in California.

See all family practice providers in California

Medicare billing

Part B allowed, 2024
$24,988
Medicare patients
64
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide14$27,261
EliquisApixaban14$17,639
JardianceEmpagliflozin21$16,844
XareltoRivaroxaban12$14,933
Synjardy XrEmpagliflozin/Metformin Hcl14$14,602
Atorvastatin Calcium113$789
Acamprosate Calcium13$782
Estradiol12$733
Levothyroxine Sodium54$661
Albuterol Sulfate HfaAlbuterol Sulfate22$592
Metoprolol Succinate25$474
Losartan Potassium64$457
Metformin Hcl ErMetformin Hcl18$422
Amlodipine Besylate94$387
Mirtazapine14$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$94$27,26114 claims
PfizerEliquis$129$17,63914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,195 family practice providers in California.

Other family practice in French Camp

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →